PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Perioperative Tislelizumab Preserves Quality of Life and Eases Chest Pain, Cough in NSCLC

tislelizumabanti-PD-1 monoclonal antibodyimmune checkpoint inhibitorplatinum-doublet chemotherapyresectable NSCLCstage II–IIIAperioperativeneoadjuvantadjuvantpatient-reported outcomesQLQ-C30QLQ-LC13RATIONALE-315phase III RCT Oncology

Background Information

Tislelizumab improves lung cancer patients' quality of life by reducing symptoms.

This study evaluates patient-reported outcomes (PROs) in the use of tislelizumab plus chemotherapy for resectable NSCLC, highlighting its impact on quality of life measures. Patients receiving tislelizumab showed less chest pain and improved coughing than those on placebo, with significant differences observed during adjuvant therapy. While promising, the study is specific to perioperative treatment settings and focused on PROs, not directly altering current pharmacy practice yet. Tislelizumab plus chemotherapy shows benefits in managing symptoms like chest pain and coughing in resectable NSCLC.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Yue D, Cappuzzo F, Wang W, Liu H, Chen Q, Wang S, Leaw SJ, Yao B, Barnes FB, Barnes G, Wang C

Citation: Yue D, Cappuzzo F, Wang W, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial. Future oncology (London, England). 2026;22(24):2911-2921. doi:10.1080/14796694.2026.2743385

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.